13 research outputs found
Recommended from our members
Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata
Erythema nodosum (EN) is a form of septal panniculitis, which is believed to represent a delayed hypersensitivity reaction activated by infectious agents, drugs, granulomatous and autoimmune diseases, pregnancy, and malignancies. There are only four reported cases of EN during oral isotretinoin therapy to our knowledge, all of them occurring in patients with severe acne. Since acne itself can trigger EN, the question as to whether there is indeed a causative relationship between isotretinoin and EN in the reported cases remains to be elucidated. We present herein a 20-year-old woman with multiple vulvar condylomata acuminata who developed EN two weeks after onset of oral isotretinoin therapy. To the best of our knowledge, this is the first report of EN occurring during isotretinoin treatment in a patient without acne and strongly indicates that the pathogenesis of EN can be directly related to the biological actions of isotretinoin. Erythema nodosum should be regarded as a rare side effect of oral isotretinoin therapy, regardless of the underlying disease. Physicians should be aware of this rare side effect
Topical imiquimod is and effective and safe drug for molluscum contagiosum in children
No abstract available.</p
Pyogenic Granuloma on Facial Skin Associated With Long-Term Topical Application of Tacrolimus: Pyogenic granuloma ans tacrolimus
Pyogenic granuloma (PG) is a benign vascular neoplasm of the skin and mucous membranes, the exact cause and pathogenesis of which still remain unknown. PG typically occurs in the form of solitary and rarely multiple, rapidly developing, glistering, hemorrhagic and ulceration-prone, pink or purple, angiomatous papule or nodule. Proposed stimuli for the occurrence of PG include minor trauma and chronic irritation, infections, viral oncogenes, pregnancy, microscopic arteriovenous anastomoses and diverse drugs. Tacrolimus is a macrolide, produced by the Streptomyces Ttsukubaensis, which exerts potent immunosuppressive action through inhibition of calcineurin. Topically applied tacrolimus has been approved for the treatment of patients with moderate to severe atopic dermatitis unresponsive or intolerant to conventional regimens, but it has also been used as an off-label treatment for various cutaneous diseases. We report a 35-year-old man who developed PG on his face after a long-term topical application of tacrolimus ointment for the treatment of seborrheic dermatitis. The patient didn’t recall any trauma or other chronic irritation at the site of his recently emerging solitary lesion, whereas other predisposing factors for PG were excluded. To the best of our knowledge the case presented here is the first report of this adverse reaction. PG should be considered as a possible side-effect of topical application of tacrolimus and dermatologists should be able to diagnose and properly treat it
Galectins 7 and 9 in Dermatology : Current knowledge and future perspectives
Galectins constitute a family of β-galactoside-binding proteins lectins that are widely distributed in nature occurring in mammals, sponges, fungi, nematodes, insects and viruses. Galectins are involved in fundamental cellular processes in human skin and other tissues and exert biological effects of paramount importance through interactions with cytoplasmic and nuclear proteins and with components of cell surface and extracellular matrix, as well.In this paper we summarize current knowledge on the expression of galectins 7 and 9 in normal and diseased human skin and present the future perspectives of the use of these galectins or their antagonists/inhibitors in the diagnosis, prognosis and treatment of cutaneous disorders
Recommended from our members
Golimumab-associated persistent erythema multiforme in a patient with ulcerative colitis in full remission
Erythema multiforme is an immune-mediated cutaneous disorder that is thought to represent a hypersensitivity reaction to infections, drugs, vaccines, malignancies, autoimmune diseases, radiation, and menstruation. Golimumab is a human IgG1-kappa anti-TNF antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. We report herein a 41-year-old woman with persistent erythema multiforme, that occurred 18 months after onset of golimumab treatment of her ulcerative colitis; the latter remains in full remission over a period of 36 months
Recommended from our members
Late-onset pseudoepitheliomatous hyperplasia developing within a red ink tattoo
The popularity of tattoos has increased dramatically worldwide particularly in the last three decades, giving rise to the frequent occurrence of a wide spectrum of secondary cutaneous and systemic complications. Pseudoepitheliomatous hyperplasia (PEH) is a benign irregular hyperplasia of the epidermis occurring in response to various stimuli, that clinically and histopathologically resembles cutaneous neoplasms such as squamous cell carcinoma and keratoacanthoma. In an attempt to improve the awareness of the possible occurrence of PEH in tattoos and of its diagnostic and therapeutic aspects, we present herein the case of a 30-year-old woman with histologically confirmed PEH related to a red-ink tattoo. She revealed two important features: the longest interval reported so far between tattooing and onset of PEH (two years) and the lack of the otherwise very common lichenoid tissue reaction to red ink. In view of the serious toxicological potential of tattoo inks, implementation of updated and standardized regulations worldwide regarding their use in the tattooing process is now urgently warranted and continuous efforts should be undertaken in order to enhance the awareness among tattoo artists and the public with regard to the possible serious health risks associated with the use of tattoo ink pigments
Recommended from our members
Golimumab-associated persistent erythema multiforme in a patient with ulcerative colitis in full remission
Erythema multiforme is an immune-mediated cutaneous disorder that is thought to represent a hypersensitivity reaction to infections, drugs, vaccines, malignancies, autoimmune diseases, radiation, and menstruation. Golimumab is a human IgG1-kappa anti-TNF antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. We report herein a 41-year-old woman with persistent erythema multiforme, that occurred 18 months after onset of golimumab treatment of her ulcerative colitis; the latter remains in full remission over a period of 36 months
Recommended from our members
Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata
Erythema nodosum (EN) is a form of septal panniculitis, which is believed to represent a delayed hypersensitivity reaction activated by infectious agents, drugs, granulomatous and autoimmune diseases, pregnancy, and malignancies. There are only four reported cases of EN during oral isotretinoin therapy to our knowledge, all of them occurring in patients with severe acne. Since acne itself can trigger EN, the question as to whether there is indeed a causative relationship between isotretinoin and EN in the reported cases remains to be elucidated. We present herein a 20-year-old woman with multiple vulvar condylomata acuminata who developed EN two weeks after onset of oral isotretinoin therapy. To the best of our knowledge, this is the first report of EN occurring during isotretinoin treatment in a patient without acne and strongly indicates that the pathogenesis of EN can be directly related to the biological actions of isotretinoin. Erythema nodosum should be regarded as a rare side effect of oral isotretinoin therapy, regardless of the underlying disease. Physicians should be aware of this rare side effect